Literature DB >> 18931355

Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.

N S Sieber-Ruckstuhl1, F S Boretti, M Wenger, C Maser-Gluth, C E Reusch.   

Abstract

The serum concentrations of cortisol and cortisone were measured in 19 healthy dogs and in 13 dogs with pituitary-dependent hyperadrenocorticism (PDH) before and one hour after an injection of synthetic adrenocorticotropic hormone (ACTH). In the dogs with pdh, the cortisol and cortisone concentrations were measured before and after one to two weeks and three to seven weeks of treatment with trilostane. The dogs with PDH had significantly higher baseline and poststimulation concentrations of cortisol and cortisone, and higher baseline cortisol:cortisone ratios than the healthy dogs. During the treatment with trilostane, the poststimulation cortisol, the baseline and poststimulation cortisone concentrations, and the baseline and poststimulation cortisol:cortisone ratios decreased significantly. The decrease in poststimulation cortisone was significantly smaller than the decrease in cortisol.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931355     DOI: 10.1136/vr.163.16.477

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  2 in total

1.  Urinary corticoid concentrations measured by 5 different immunoassays and gas chromatography-mass spectrometry in healthy dogs and dogs with hypercortisolism at home and in the hospital.

Authors:  L Galeandro; N S Sieber-Ruckstuhl; B Riond; S Hartnack; R Hofmann-Lehmann; C E Reusch; F S Boretti
Journal:  J Vet Intern Med       Date:  2014-07-16       Impact factor: 3.333

2.  Cortisol Response in Healthy and Diseased Dogs after Stimulation with a Depot Formulation of Synthetic ACTH.

Authors:  N S Sieber-Ruckstuhl; W A Burkhardt; N Hofer-Inteeworn; B Riond; I T Rast; R Hofmann-Lehmann; C E Reusch; F S Boretti
Journal:  J Vet Intern Med       Date:  2015-10-27       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.